Immunotherapy for oesophagogastric cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide [Internet]. Int Agency for Res Cancer. [cited 2016 Apr 29]. Available from: http://globocan.iarc.fr
   Google Scholar
• Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3). Article No. CD004064. doi:10.1002/14651858.CD004064.pub3.
   Google Scholar
• Iacovelli R, Pietrantonio F, Farcomeni A, et al. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. PLoS One. 2014;9(9):e108940. doi:10.1371/journal.pone.0108940.
   PubMed Web of Science ®Google Scholar
• Bass AJ, Thorsson V, Shmulevich I, et al., Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513(7517): 202–209. 2014. doi:10.1038/nature13480.
   PubMed Web of Science ®Google Scholar
• Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–95. doi:10.1038/nature13176.
   PubMed Web of Science ®Google Scholar
• Pennock GK, Chow LQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812–822. doi:10.1634/theoncologist.2014-0422.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell. 1987;49(2):273–280. doi:10.1016/0092-8674(87)90568-X.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi:10.1038/nri3405.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.05.019.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–146. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Kessels HWHG, De Visser KE, Tirion FH, et al. The impact of self-tolerance on the polyclonal CD8+ T cell repertoire. J Immunol. 2004;172(4):2324–2331. doi:10.4049/jimmunol.172.4.2324.
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005;5(10):772–782. doi:10.1038/nri1707.
   PubMed Web of Science ®Google Scholar
• Simpson AJG, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615–625. doi:10.1038/nrc1669.
   PubMed Web of Science ®Google Scholar
• Zhang GL, Ansari HR, Bradley P, et al. Machine learning competition in immunology – Prediction of HLA class I binding peptides. J Immunol Methods. 2011;374(1–2):1–4. doi:10.1016/j.jim.2011.09.010.
   PubMed Web of Science ®Google Scholar
• Martin SD, Coukos G, Holt RA, et al. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol. 2015;26(12):2367–2374. doi:10.1093/annonc/mdv383.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJS, Rosenthal R, et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 351(6280): 1463–1469. 2016. doi:10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature12477.
   PubMed Web of Science ®Google Scholar
• Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436–444. doi:10.1136/jmg.2009.074237.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Grady W, Suriano G, et al. Gastric cancer: new genetic developments. J Surg Oncol. 2005;90:114–133. doi:10.1002/(ISSN)1096-9098.
   PubMed Web of Science ®Google Scholar
• Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–362. doi:10.3748/wjg.v12.i3.354.
   PubMed Web of Science ®Google Scholar
• Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8(4):437–447.
   PubMed Web of Science ®Google Scholar
• Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133(2):659–672. doi:10.1053/j.gastro.2007.06.026.
   PubMed Web of Science ®Google Scholar
• Sepulveda AR. Helicobacter, inflammation, and gastric cancer. Curr Pathobiol Rep. 2013;1(1):9–18. doi:10.1007/s40139-013-0009-8.
   PubMedGoogle Scholar
• Kim JJ, Tao H, Carloni E, et al. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology. 2002;123(2):542–553. doi:10.1053/gast.2002.34751.
   PubMed Web of Science ®Google Scholar
• Machado AMD, Figueiredo C, Touati E, et al. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res. 2009;15(9):2995–3002. doi:10.1158/1078-0432.CCR-09-0547.
   PubMed Web of Science ®Google Scholar
• Giampieri R, Maccaroni E, Mandolesi A, et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy [Internet]. Gastric Cancer. 2016. [cited 2016 Apr 29]. Available from: http://link.springer.com.ezproxy.icr.ac.uk/article/10.1007%2Fs10120-016-0594-4
   PubMedGoogle Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Iizasa H, Nanbo A, Nishikawa J, et al. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses. 2012;4(12):3420–3439. doi:10.3390/v4102014.
   PubMed Web of Science ®Google Scholar
• Gillison M, Blumenscein G, Fayette J et al. Nivolumab (nivo) vs investigator’s choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans (LA). Philadelphia (PA): AACR; 2016. Abstract no. CT099.
   Google Scholar
• Davidson M, Okines AFC, Starling N. Current and future therapies for advanced gastric cancer. Clin Colorectal Cancer. 2015;14(4):239–250. doi:10.1016/j.clcc.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–39. doi:10.1016/S0140-6736(13)61719-5.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Cutsem EV, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235. doi:10.1016/S1470-2045(13)70510-2.
   PubMed Web of Science ®Google Scholar
• Inoue H, Mori M, Honda M, et al. The expression of tumor-rejection antigen “MAGE” genes in human gastric carcinoma. Gastroenterology. 1995;109(5):1522–1525. doi:10.1016/0016-5085(95)90639-8.
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Yamazaki T, Fujita T, et al. Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen. Tumour Biol. 2012;33(6):1881–1887. doi:10.1007/s13277-012-0448-6.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Z-H, Zhou -J-J, et al. Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice. Chin J Cancer. 2010;29(4):359–364. doi:10.5732/cjc.009.10541.
   PubMedGoogle Scholar
• Ajani JA, Hecht JR, Ho L, et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006;106(9):1908–1916. doi:10.1002/cncr.21730.
   PubMed Web of Science ®Google Scholar
• Masuzawa T, Fujiwara Y, Okada K, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41(4):1297–1304.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–277. doi:10.1038/nrc3258.
   PubMed Web of Science ®Google Scholar
• Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8(11):3394–3400.
   PubMed Web of Science ®Google Scholar
• Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res. 2001;7(8):2277–2284.
   PubMed Web of Science ®Google Scholar
• Leslie NR, Batty IH, Maccario H, et al. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene. 2008;27(41):5464–5476. doi:10.1038/onc.2008.243.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kang TH, Noh KH, et al. Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol. 2011;165(2):180–189. doi:10.1111/j.1365-2249.2011.04410.x.
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115(12):3623–3633. doi:10.1172/JCI25947.
   PubMed Web of Science ®Google Scholar
• Subhash VV, Yeo MS, Tan WL, et al. Strategies and advancements in harnessing the immune system for gastric cancer immunotherapy. J Immunol Res. 2015;2015:1–14. doi:10.1155/2015/308574. article ID 308574
   Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-0116.
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123(17):2625–2635. doi:10.1182/blood-2013-11-492231.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lim J, Kang JS, et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res. 2010;33(11):1789–1795. doi:10.1007/s12272-010-1111-7.
   PubMed Web of Science ®Google Scholar
• Cui J, Li L, Wang C, et al. Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy. 2015;17(7):979–988. doi:10.1016/j.jcyt.2015.03.605.
   PubMed Web of Science ®Google Scholar
• Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8(6):1767–1771.
   PubMed Web of Science ®Google Scholar
• Singh H, Moyes JSE, Huls MH, et al. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther. 2015;22(2):95–100. doi:10.1038/cgt.2014.69.
   PubMed Web of Science ®Google Scholar
• Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169–180. doi:10.1097/CJI.0b013e318194a6e8.
   PubMed Web of Science ®Google Scholar
• Ito A, Kondo S, Tada K, et al. Clinical development of immune checkpoint inhibitors. Biomed Res Int. 2015;2015:1–12. doi:10.1155/2015/605478. article ID 605478
   Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16(20):1662–1672. doi:10.1158/1078-0432.CCR-10-0613.
   PubMed Web of Science ®Google Scholar
• Segal N, Antonia S, Brahmer J, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol. 2014;32(5s). (suppl; abstr 3002^). doi:10.1200/JCO.2013.54.6911.
   PubMed Web of Science ®Google Scholar
• Chung C, Arkenau H, Wyrwicz L, et al. Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer [Internet]. J Clin Oncol. 2016;34(suppl 4S; abstr 167). [cited 2016 Apr 29]. Available from: http://meetinglibrary.asco.org/content/160166-173
   Google Scholar
• Muro K, Bang Y, Shankaran V, et al. LBA15 A phase 1b study of pembrolizumab in patients with advanced gastric cancer [Internet]. Ann Onc. 2014;25(suppl_4). [cited 2016 Apr 29]. Available from: http://annonc.oxfordjournals.org/citmgr?gca=annonc%3B25%2Fsuppl_4%2Fmdu438.15
   Google Scholar
• Doi T, Piha-Paul A, Jalal S, et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J Clin Oncol. 2016; 34(suppl 4S; abstr 7) . [cited 2016 Apr 29]. Available from: http://meetinglibrary.asco.org/content/160127-173
   PubMedGoogle Scholar
• Dung T, Bendell J, Calvo E, et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study [Internet]. J Clin Oncol. 2016; 34(suppl 4S; abstr 6) . [cited 2016 Apr 29]. Available from: http://meetinglibrary.asco.org/content/160127-173
   Google Scholar
• Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–1725. doi:10.1084/jem.20082492.
   PubMed Web of Science ®Google Scholar
• Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517–2519. doi:10.1056/NEJMoa1114705.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi:10.1084/jem.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477. doi:10.1038/nri2326.
   PubMed Web of Science ®Google Scholar
• Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:1–8. doi:10.1155/2012/656340. article ID 656340
   Google Scholar
• Muro K, Bang Y-J, Shankaran V. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012 [Internet]. J Clin Oncol. 2015;33(suppl 3; abstr 3). [cited 2016 Apr 29]. Available from: http://meetinglibrary.asco.org/content/140536-158
   Web of Science ®Google Scholar
• Callahan M, Bendell J, Chan E, et al. Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. J Clin Oncol. 2014;32(5s). (suppl; abstr TPS3114). doi:10.1200/JCO.2013.54.6911.
   Web of Science ®Google Scholar
• Herbst R, Gordon M, Fine G, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31(suppl; abstr 3000). doi:10.1200/JCO.2013.49.0219.
   Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(1):4275–4280. doi:10.1073/pnas.0910097107.
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. doi:10.1016/j.ctrv.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi:10.1158/1078-0432.CCR-09-0547.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kalos M, Schaer DA, et al. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013;19(5):1009–1020. doi:10.1158/1078-0432.CCR-12-2982.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038/nrc.2016.36.
   PubMed Web of Science ®Google Scholar
• Ribas A, Robert C, Hodi F, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature [Internet]. J Clin Oncol. 2015; 33(suppl; abstr 3001) . [cited 2016 Apr 29]. Available from: http://meetinglibrary.asco.org/content/151652-156
   PubMed Web of Science ®Google Scholar
• Shankaran V, Muro K, Bang Y-J-J, et al. Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475) [Internet]. J Clin Oncol. 2015;33(suppl; abstr 3026).
   Google Scholar
• Bang Y-J, Chung HC, Shankaran V, et al. LBA-04 * Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012. Ann Oncol. 2015;26(suppl4):iv117–iv121. doi:10.1093/annonc/mdv262.4
   Google Scholar
• Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(1):350–366. doi:10.1002/path.2730.
   PubMed Web of Science ®Google Scholar
• Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751–759. doi:10.1007/s00262-012-1253-1.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Teng MWL, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(21):2139–2145. doi:10.1158/0008-5472.CAN-14-3569.
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443. doi:10.1158/2326-6066.CIR-15-0064.
   PubMed Web of Science ®Google Scholar
• Terme M, Colussi O, Marcheteau E, et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012;2012:1–8. doi:10.1155/2012/492920.
   Google Scholar
• Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol. 2013;172(3):500–506. doi:10.1111/cei.12069.
   PubMed Web of Science ®Google Scholar
• Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561–17566. doi:10.1073/pnas.1215397109.
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259–267. doi:10.1038/sj.bjc.6602930.
   PubMed Web of Science ®Google Scholar
• Stagg J, Loi S, Divisekera U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108(17):7142–7147. doi:10.1073/pnas.1016569108.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931. doi:10.1056/NEJMoa1114705.
   PubMed Web of Science ®Google Scholar
• Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–372. doi:10.1158/2326-6066.CIR-13-0115.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780. doi:10.4161/onci.28780.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi:10.1172/JCI67313.
   PubMed Web of Science ®Google Scholar
• Park SS, Dong H, Liu X, et al. PD-1 Restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610–619. doi:10.1158/2326-6066.CIR-14-0138.
   PubMed Web of Science ®Google Scholar
• Victor CT-S, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377. doi:10.1038/nature14292.
   PubMed Web of Science ®Google Scholar
• Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 2016;6:703–713. doi:10.1158/2159-8290.CD-16-0146. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–581. doi:10.1038/nature13988.
   PubMed Web of Science ®Google Scholar